To the Editor We recently reported a phase I dose-escalation study of the oral tyrosine kinase inhibitor vorolanib (previously known as X-82 [Tyrogenex]), which was used as a treatment for neovascular age-related macular degeneration (AMD).1 We have since been made aware of a 2008 report detailing 2 cases of neovascular AMD treated with oral sorafenib, which deserves mention.2 Like vorolanib, sorafenib is a multikinase inhibitor that has been used to treat cancer. It has theoretical utility as a treatment for wet AMD because it downregulates the production of vascular endothelial growth factor and platelet-derived growth factor.
Jackson TL, Boyer D, Rosenfeld PJ. Oral Tyrosine Kinase Inhibitors for Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2019;137(7):854–855. doi:10.1001/jamaophthalmol.2019.0861
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: